| 9.23 -0.2 (-2.12%) | 07-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 11.42  |
1-year : | 12.35 |
| Resists | First : | 9.78 |
Second : | 10.57 |
| Pivot price | 9.86 |
|||
| Supports | First : | 8.48 |
Second : | 7.06 |
| MAs | MA(5) : | 9.43 |
MA(20) : | 9.88  |
| MA(100) : | 9.48 |
MA(250) : | 7.34 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 16.1 |
D(3) : | 18 |
| RSI | RSI(14): 43.4 |
|||
| 52-week | High : | 11.65 | Low : | 4.15 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VIR ] has closed above bottom band by 8.7%. Bollinger Bands are 20.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.61 - 9.65 | 9.65 - 9.69 |
| Low: | 8.98 - 9.05 | 9.05 - 9.1 |
| Close: | 9.14 - 9.24 | 9.24 - 9.31 |
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
Fri, 17 Jul 2026
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Fri, 17 Jul 2026
Vir Biotechnology (VIR) Bank of America Global Healthcare Conference 2026 Summary - Quartr
Thu, 16 Jul 2026
Vir Biotechnology: Multiple Catalysts In Hepatitis And Oncology Ahead (NASDAQ:VIR) - Seeking Alpha
Thu, 16 Jul 2026
Hillsdale Investment Management Inc. Invests $1.44 Million in Vir Biotechnology, Inc. $VIR - MarketBeat
Mon, 29 Jun 2026
Vir Biotechnology, Inc. SEC Filing (Jun 29, 2026) - Stock Titan
Sun, 07 Jun 2026
Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 169 (M) |
| Held by Insiders | 1.2876e+008 (%) |
| Held by Institutions | 6.5 (%) |
| Shares Short | 18,320 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.5105e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 459 % |
| Return on Assets (ttm) | 241.3 % |
| Return on Equity (ttm) | -24.8 % |
| Qtrly Rev. Growth | 6.55e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -29.44 |
| EBITDA (p.s.) | -2.29136e+008 |
| Qtrly Earnings Growth | -3.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -446 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.32 |
| Price to Cash Flow | 2.72 |
| Dividend | 0 |
| Forward Dividend | 1.919e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|